Based on their mechanism of action, targeting either the CGRP or the CGRPr, four anti-CGRP MAbs have been approved for clinical use in migraine prevention by the regulatory authorities based on compelling results of RCTs to support an excellent efficacy/safety profile [78]. Here, CALCRL is linked to migraine disorder.